exa-cel
vertex pharmaceuticals,CRISPR therapeutics AG
[]
$crsp still looks bloody good, at least in sickle cell disease and beta-thalassaemia. so why are shares down 13%? the take on the exa-cel #eha2022 data 
News Editor for Vantage covering biopharma and medtech; cat lover; banana run winner